Skip to content

Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction

Synthetic Bone Graft Substitute (Actifuse) vs. Autologous Spongiosa for Tunnel Enlargement in Revision Anterior Cruciate Ligament Reconstruction - a Histological and Radiological Assessment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02845141
Enrollment
40
Registered
2016-07-27
Start date
2013-03-31
Completion date
2017-07-31
Last updated
2018-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Cruciate Ligament Injury

Keywords

ACL, Revision surgery, tunnel enlargement, bone substitute material, bone graft

Brief summary

The overall objective is the histological and radiological assessment of bony consolidation of the tibial/femoral tunnel using either bone graft substitute (Actifuse) or autologous spongiosa in patients undergoing revision anterior cruciate ligament reconstruction. Clinical correlation with the histological and radiological results using the SF36 questionnaire.

Detailed description

\* Study design: Monocentric, prospective, randomised study. Patients who need revision anterior cruciate ligament reconstruction and show a tunnel enlargement of \>10mm will have a first operation filling the tibial/femoral tunnel either with bone graft substitute (Actifuse) or autologous spongiosa. 5 - 6 months after this first operation a CT will be performed to assess the bony consolidation of the former tibial/femoral tunnel. An MRI will be performed to assess vitality of the bone substitute. An osseous biopsy will be taken from the tibial/femoral tunnel at the revision anterior cruciate ligament reconstruction approximately 6 months after bone grafting. Clinical evaluation will be performed 6 weeks, 3 months and 6 months postoperative. At 6 months postoperative additional radiological evaluation and clinical assessment using the SF36 questionnaire will be performed. * Treatment: Either autologous spongiosa or Actifuse (MIS applicator) will be administered by the investigator as a bone graft substitute for tunnel enlargement in patients undergoing revision anterior cruciate ligament reconstruction. * Duration of Participation: The participation of each subject will be approximately 12 months. Each subject will undergo revision anterior cruciate ligament reconstruction approximately 6 months after bone grafting. A biopsy will be taken at this operation. A clinical and radiological follow up is planned for further 6 months. \* Subjects: Male and female patients ≥ 18 years. Approximately 40 patients who undergo revision anterior cruciate ligament reconstruction will be included in the study. Inclusion criteria: Patients in need of revision anterior cruciate ligament reconstruction Exclusion criteria: Infection, wound healing complications

Interventions

PROCEDUREActifuse

bone tunnel filled with Actifuse

PROCEDUREbone graft

bone graft to fill bone tunnel

Sponsors

Berufsgenossenschaftliche Unfallklinik Ludwigshafen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients in need of revision anterior cruciate ligament reconstruction

Exclusion criteria

* Infection, wound healing complications

Design outcomes

Primary

MeasureTime frameDescription
histological assessment of bony consolidation6 months postophistological probes during second intervention to measure bony ingrowth into bone substitute material

Secondary

MeasureTime frameDescription
Tegner Activity Score3, 6 and 12 Monthsfunctional score
IKDC Score3, 6 and 12 Monthsfunctional score
stability measurement using KT10003, 6 and 12 Monthsfunctional score
SF36-Score3, 6 and 12 Monthshealth score

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026